CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Another Nail in the Coffin for Intra-Aortic Balloon Counterpulsion in Acute Myocardial Infarction With Cardiogenic Shock Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Scientific Statement From the American Heart Association Appropriate Use Criteria and Health Status Outcomes Following Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the OPEN-CTO Registry Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction Outcome of Applying the ESC 0/1-hour Algorithm in Patients With Suspected Myocardial Infarction Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease-a nationwide study A Test in Context: E/A and E/e' to Assess Diastolic Dysfunction and LV Filling Pressure Association of Body Mass Index With Lifetime Risk of Cardiovascular Disease and Compression of Morbidity Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome: A Pilot Randomized Controlled Trial

Review Article03 January 2020

JOURNAL:Eur Heart J. Article Link

Clinical impact of conduction disturbances in transcatheter aortic valve replacement recipients: a systematic review and meta-analysis

L Faroux, S Chen, J Rodés-Cabau et al. Keywords: heart failure; left bundle-branch block; proton pump inhibitors; persistence pacemaker;permanent transcatheter aortic-valve implantation

ABSTRACT


AIMS - The clinical impact of new-onset persistent left bundle branch block (NOP-LBBB) and permanent pacemaker implantation (PPI) on transcatheter aortic valve replacement (TAVR) recipients remains controversial. We aimed to evaluate the impact of (i) periprocedural NOP-LBBB and PPI post-TAVR on 1-year all-cause death, cardiac death, and heart failure hospitalization and (ii) NOP-LBBB on the need for PPI at 1-year follow-up.

 

METHODS AND RESULTS - We performed a systematic search from PubMed and EMBASE databases for studies reporting raw data on 1-year clinical impact of NOP-LBBB or periprocedural PPI post-TAVR. Data from 30 studies, including 7792 patients (12 studies) and 42 927 patients (21 studies) for the evaluation of the impact of NOP-LBBB and PPI after TAVR were sourced, respectively. NOP-LBBB was associated with an increased risk of all-cause death [risk ratio (RR) 1.32, 95% confidence interval (CI) 1.171.49; P < 0.001], cardiac death (RR 1.46, 95% CI 1.201.78; P < 0.001), heart failure hospitalization (RR 1.35, 95% CI 1.051.72; P = 0.02), and PPI (RR 1.89, 95% CI 1.582.27; P < 0.001) at 1-year follow-up. Periprocedural PPI after TAVR was associated with a higher risk of all-cause death (RR 1.17, 95% CI 1.111.25; P < 0.001) and heart failure hospitalization (RR 1.18, 95% CI 1.031.36; P = 0.02). Permanent pacemaker implantation was not associated with an increased risk of cardiac death (RR 0.84, 95% CI 0.671.05; P = 0.13).

 

CONCLUSION - NOP-LBBB and PPI after TAVR are associated with an increased risk of all-cause death and heart failure hospitalization at 1-year follow-up. Periprocedural NOP-LBBB also increased the risk of cardiac death and PPI within the year following the procedure. Further studies are urgently warranted to enhance preventive measures and optimize the management of conduction disturbances post-TAVR.